Our indicators are actually little changed this week. Bonds are overbought, but not so much as to justify a short position here. Likewise, it wouldn’t surprise us if the Dow and S&P 500 soon took a short breather now that they’re once more flirting with their highs. But here again,… Read More
Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.
Analyst Articles
Average Annualized Return Per Closed Trade: 34.8% Average Return Per Closed Trade: 19.7% Average Holding Period: 220 days This week, we take a look at the results reported by two of our recommendations, the hot Chinese online retailer stock that has gained roughly 30 percent since joining our portfolio less than 3 months ago, and the recent diagnostic testing biotech stock that we added just last week. Read More
Stocks are little changed today after two days of gains, with little news to propel them in either direction. What news we have had, however, has largely been positive. The U.S. National Federation Independent Business’ Optimism Index inched higher in July and remains near the seven-year high touched in May. Read More
Gold has been acting a little better in recent days. From a technical perspective we’d like to see it settle at prices somewhat higher than where they stand now, and stay there for several consecutive days. Building a base in the range of $1,320 to $1,325 would likely heighten buyer… Read More
Average Annualized Return Per Closed Trade: 34.8% Average Return Per Closed Trade: 19.7% Average Holding Period: 220 days Earlier this week, we followed the lead of another top hedge fund and added another Brain Trust Profits pick to our portfolio. This company is a leading molecular diagnostic company specializing in developing and marketing tests that assess a person’s risk of developing disease, provides information to guide treatment decisions and evaluate the risk of disease progression and recurrence. Read More
No sooner did we describe the market as being unflappable (in the last update headline, no less) than stocks produced their worst weekly performance in two years. Still, we stand by that call. Although equities did slip in last week’s trading, from where we sit it looks like nothing more… Read More
One reason we’re not overly concerned about the short-term prospects for stocks is the recent lack of buying interest in precious metals, typically a safe haven when stocks come under pressure. But although gold could trade sideways to slightly lower in the near term, its long-term prospects are undiminished. Stick… Read More
Buy Myriad Genetics (MYGN). Iridian Asset Management is a tremendously successful hedge fund under the leadership of two seasoned Wall Street gurus, David Cohen and Harold Levy. Co-founded by the two men in 1996, the fund specializes in mid-cap and small-cap equities, and has about $13 billion in assets under… Read More
Average Annualized Return Per Closed Trade: 34.8% Average Return Per Closed Trade: 19.7% Average Holding Period: 220 days The Bureau of Labor Statistics reported today that U.S. employers added 209,000 jobs in July, less than the 230,000 gain economists expected. However, the increase represented the sixth consecutive gain of more than 200,000 jobs, the longest such streak since the late 1990s. The headline unemployment rate rose slightly to 6.2 percent as more people entered the labor force. The payrolls increases from May and June were also revised upward by a total of 15,000. The worrisome June 523,000 drop in full-time jobs reversed to a 285,000 gain last month, but average hourly wages remained essentially flat. Read More
Tensions in Europe continue to mount in the wake of a seeming step-up in Russian support of Ukrainian separatists following the success of Ukrainian government troops in recapturing territory formerly held by the rebels—despite widespread condemnation of the downing of Malaysia Airlines MK17. The European Union has enacted stiffer sanctions… Read More